Most of the retatrutide conversation in 2026 has been about numbers — 28.3%, 30.3%, 22.6%. But the genuinely new development this quarter isn't a weight-loss figure at all. It's a door. In August, Eli Lilly confirmed it has built a formal pre-approval expanded access programme for retatrutide, and registered it publicly. So if you've been asking when will retatrutide be available, the honest 2026 answer now has two parts: general availability is still waiting on a regulatory filing Lilly says is coming in the first quarter of 2027 — but a narrow, physician-gated pre-approval pathway already exists today, and the doctors who'd have to use it are openly split on whether they will.

When Will Retatrutide Be Available? What Changed in August

The backstory matters. In April 2026, a single 79-year-old patient was granted access to retatrutide through the FDA's compassionate use mechanism, following a request filed by a senior clinician at the US National Institutes of Health. STAT's reporting on that case in June raised uncomfortable questions about why one individual had received something no other patient could get.

The pushback came from obesity physicians, not patients. Within weeks, clinicians were asking Lilly for the same route for their own cases. On 3 August 2026, Lilly confirmed it would allow other patients to apply, saying that for a limited number of people who meet specific medical criteria and cannot enrol in a clinical trial, it believes it is medically appropriate to make authentic retatrutide available before FDA approval — and that it is actively reviewing requests from healthcare providers.

That programme is now a public record: ClinicalTrials.gov entry NCT07629401, "Provide Pre-approval Expanded Access of LY3437943," listed as available. It is not a trial. It enrols no cohort, tests no hypothesis and generates no efficacy data. It is a supply mechanism.

The criteria are deliberately narrow

Per the registry listing, a patient must be 18 or over and meet all of the following:

  • Refractory obesity — a BMI of 35 kg/m² or above despite adherence to, and tolerance of, the highest available dose of an approved chronic weight management therapy
  • Two or more serious or life-threatening obesity-related complications, for which they are currently receiving standard of care
  • Unable to participate in an ongoing trial of retatrutide or a comparable investigational medicine — because of eligibility criteria or because there's no reasonably accessible enrolling site
  • All standard options discussed, including bariatric surgery, through shared decision-making

A medical contraindication to retatrutide is an exclusion. Read the first criterion carefully: this is explicitly for people in whom tirzepatide or semaglutide at maximum dose has already failed. It is not an early-access queue for people who'd simply prefer the triple agonist.

The Patient Isn't the Applicant

This is the part most coverage skips. Under expanded access, a patient cannot apply directly. The treating physician submits the request to the sponsor; if the sponsor agrees to supply, the physician then files with the FDA and an institutional review board. Three separate parties have to say yes, and the first one is a doctor who has to volunteer to do the paperwork and carry the clinical responsibility.

That's where the friction is. Medscape's reporting found clinician views genuinely mixed. Fatima Cody Stanford of Harvard Medical School and Gitanjali Srivastava of Vanderbilt University Medical Center both said they were not yet pursuing compassionate use for their patients, wanting more retatrutide safety data before using it outside a monitored trial setting. Other obesity specialists described prolonged silence or vague replies to their applications, and called for transparency on how requests are triaged, what the timelines are, and whether treatment has to be administered at a trial site. One characterisation in Medscape's follow-up coverage was blunt: the pathway is more of an obstacle than a bridge, and it risks pitting the doctor against the patient.

Both positions are defensible. Expanded access exists precisely for patients who have run out of options. It also means giving an unapproved drug to a complex, high-risk population outside the monitoring structure that makes clinical trials safe.

Why the Safety Caution Is Reasonable

The efficacy case for retatrutide is now substantial. TRIUMPH-1, presented in 2026, reported average weight loss of 28.3% at 12 mg over 80 weeks against 2.2% on placebo on the efficacy estimand, with a 104-week figure of 30.3% reported for the 12 mg arm — roughly 85 lb from an average baseline of 268.3 lb. TRIUMPH-2 in type 2 diabetes reported up to 20.8% at 80 weeks, and TRIUMPH-3 in severe obesity with established cardiovascular disease reported up to 22.6%.

But TRIUMPH-3 also delivered a result worth holding onto: three-point and five-point major adverse cardiovascular event outcomes trended favourably without reaching statistical significance. And the adverse event profile is dose-related and gastrointestinal — nausea in 28.6%, 38.4% and 42.4% of participants at 4 mg, 9 mg and 12 mg respectively versus 14.8% on placebo, with diarrhoea following a similar gradient, mostly mild to moderate and clustered during dose escalation.

Now apply that to the expanded access population: people with a BMI of 35+ and two or more serious obesity-related complications, being escalated through a dosing schedule whose side effects peak during titration, without trial-grade monitoring. The physicians asking for more data before they sign the form are not being obstructive. They're describing the actual clinical picture.

The Australian Angle: A Different Door, Same Lock

Expanded access is an FDA framework, and NCT07629401 sits inside it. Australia's structurally similar mechanisms are the TGA's Special Access Scheme and the Authorised Prescriber pathway. SAS Category B requires a prescribing practitioner to apply to the TGA for an individual patient and obtain an approval letter before supply, with applications typically processed in two to five days. The Authorised Prescriber pathway lets a registered medical practitioner treat a class of patients under their immediate care without per-patient approval.

The critical point for Australian readers is that neither pathway conjures product out of thin air. TGA authorisation permits supply; it doesn't compel a sponsor to provide an unapproved medicine. Retatrutide remains investigational and is not TGA-approved in Australia, and Lilly's stated plan is to begin regulatory filing from 2027. With roughly 66.8% of Australian adults living with overweight or obesity, the demand-side pressure here is obvious — but the supply-side decision sits with the sponsor, in every jurisdiction.

What This Actually Tells Us

Three things, none of them speculative:

  1. Lilly is now willing to supply retatrutide outside trials, under tightly drawn criteria, more than a year before its planned filing. That's a meaningful shift from the position that trial enrolment was the only route.
  2. The bottleneck has moved from the company to the clinic. The programme exists; whether it's used depends on individual physicians' risk tolerance and their patience with the application process.
  3. The regulatory clock hasn't changed. Lilly said in July 2026 it will file with the FDA in Q1 2027. Expanded access is a side door for a handful of patients, not an acceleration of approval.

Want the next TRIUMPH readout, filing milestone or regulatory update as it lands? Join the free updates list — independent, no spam.

FAQ

When will retatrutide be available?

Retatrutide is not approved anywhere as of September 2026. Eli Lilly said in July 2026 it will file for FDA approval in the first quarter of 2027, and separately operates a narrow pre-approval expanded access programme for a limited number of patients who meet strict criteria and cannot enrol in a trial.

What is retatrutide expanded access and who qualifies?

Expanded access (compassionate use) is a regulated route to an investigational drug outside a trial. Lilly's programme, registered as NCT07629401, requires a BMI of 35 or above despite maximum-dose approved weight management therapy, two or more serious obesity-related complications, and inability to join a clinical trial.

Can a patient apply for retatrutide expanded access directly?

No. The treating physician submits the request to the sponsor; if the sponsor agrees, the physician then files with the FDA and an institutional review board. Some obesity specialists have publicly described slow or vague responses to their applications.

Is retatrutide approved in Australia?

No. Retatrutide is investigational and has no TGA approval. Australia's Special Access Scheme and Authorised Prescriber pathways can permit supply of unapproved medicines, but they require a sponsor willing to supply the product — TGA authorisation alone does not create access.

Sources

This article is general information only and is not medical advice. Retatrutide is an investigational medicine and is not approved by the TGA, FDA, EMA or MHRA. Nothing here should be used to make treatment decisions — speak with a qualified Australian healthcare professional about your own circumstances. retatrutide.net.au is an independent information resource and is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.